Q-omics provides the consensus-scored PNMA8A profile across patient tissues and cancer cell-line models. PNMA8A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PNMA8A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PNMA8A RNA expression shows 19,217 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where PNMA8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA8A survival associations across molecular data types. PNMA8A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA8A RNA expression–survival associations across cancer types. High PNMA8A expression shows unfavorable associations in KIRC, but favorable associations in LUAD, COAD, GBM, UCEC and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PNMA8A RNA expression.
This table summarizes PNMA8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PNMA8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA8A shows lower tumor expression in KIRC, KICH, COAD, BLCA, THCA and BRCA. The KIRC box plot shows higher PNMA8A RNA expression in normal versus tumor tissue (log2 FC = −1.895, t-test p < 0.001).
This table shows molecular features associated with PNMA8A in patient tissues and cancer cell lines. In patient samples, PNMA8A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
